• Precision Medicine
    Categories:

    EORTC presents new precision medicine research results at AACR 2022

    13 Apr 2022

  • EMA - EORTC Workshop
    Categories:

    Joining forces to optimise cancer treatments in clinical practice: EMA & EORTC launch Cancer Medicines Forum with academia

    1 Apr 2022

  • Lung
    Categories: , ,

    MSD’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression

    17 Mar 2022

  • Mindact Breast Cancer
    Categories: ,

    Promising results for the ultra-low risk patient group in latest MINDACT analysis

    27 Jan 2022

  • NWOW
    Categories:

    New Ways of Working in a new era: EORTC new hybrid work model based on collaboration and flexibility

    19 Jan 2022

  • Researchers collaborating
    Categories:

    Independent Clinical Cancer Research in the Continuum of Drug Development into Access – for Patient-Centred Cancer Treatment & Care

    12 Jan 2022

  • Lung
    Categories: ,

    KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression

    10 Jan 2022

  • Biomedical alliance in Europe
    Categories:

    EHDS: an opportunity to unleash the power of data?

    15 Dec 2021